Skip to content

EBIT at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
CG Oncology logo
CG OncologyCGON
-$66.39M-57.3%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$57.99M-66.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.93M+27.9%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Calculated from Oric Pharmaceuticals, Inc.’s reported figures.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s EBIT?
Oric Pharmaceuticals, Inc. (ORIC) reported EBIT of -$39.62M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s EBIT changed year-over-year?
Oric Pharmaceuticals, Inc.'s EBIT decreased by 21.1% year-over-year, from -$32.72M to -$39.62M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s EBIT?
Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s EBIT has grown at a 16.0% compound annual growth rate (CAGR), from -$78.87M to -$143M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.